Literature DB >> 10691996

Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes.

C Benz1, S Angermüller, G Otto, P Sauer, W Stremmel, A Stiehl.   

Abstract

BACKGROUND/AIMS: The accumulation of endogenous bile acids contributes to hepatocellular damage during cholestatic liver disease. To evaluate the potential role of apoptotic cell death due to increased concentrations of bile acids, primary human hepatocytes were treated with hydrophobic and hydrophilic bile acids. Because the Fas receptor-ligand system may mediate apoptosis in human liver cells, the effect of toxic bile acids on hepatocellular Fas receptor expression was evaluated.
MATERIALS AND METHODS: Primary human hepatocytes were incubated with 50 and 100 microM glycochenodeoxycholic acid (GCDCA) and co-incubated with equimolar concentrations of tauroursodeoxycholic acid (TUDCA). To evaluate cytolytic and apoptotic effects, morphological alterations, hepatocellular enzyme release, nuclear DNA fragmentation and hepatocellular Fas receptor expression were evaluated.
RESULTS: Apoptotic cell death was significantly increased after exposure to 50 microM GCDCA. Bile acid-induced apoptosis was not accompanied by hepatocellular Fas receptor overexpression. Tauroursodeoxycholic acid reduced apoptosis, as indicated by a significant reduction of oligonucleosomal DNA cleavage. Fas receptor expression was not significantly affected by tauroursodeoxycholic acid. At higher concentrations, direct cytolytic cell destruction was observed.
CONCLUSION: Primary human hepatocytes represent a suitable model to study bile acid-induced apoptotic cell death. In these hepatocytes, already low bile acid concentrations might induce apoptotic cell death, which is not triggered by hepatocellular Fas receptor overexpression. Apoptotic DNA fragmentation was significantly reduced by co-incubation with tauroursodeoxycholic acid. The reduction of bile acid-induced apoptosis by ursodeoxycholic acid and its conjugates may contribute to the beneficial effects of these hydrophilic bile acids used for medical treatment of several cholestatic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691996     DOI: 10.1046/j.1365-2362.2000.00615.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  18 in total

Review 1.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 2.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

3.  Deoxycholic acid modulates cell death signaling through changes in mitochondrial membrane properties.

Authors:  Tânia Sousa; Rui E Castro; Sandra N Pinto; Ana Coutinho; Susana D Lucas; Rui Moreira; Cecília M P Rodrigues; Manuel Prieto; Fábio Fernandes
Journal:  J Lipid Res       Date:  2015-09-08       Impact factor: 5.922

4.  Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells.

Authors:  A A Powell; J M LaRue; A K Batta; J D Martinez
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

5.  Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Authors:  C Dirk Keene; Cecilia M P Rodrigues; Tacjana Eich; Manik S Chhabra; Clifford J Steer; Walter C Low
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

Review 6.  Novel insight into mechanisms of cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

7.  Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways.

Authors:  P Milkiewicz; M G Roma; E Elias; R Coleman
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

8.  GRP78 rescues the ABCG5 ABCG8 sterol transporter in db/db mice.

Authors:  Yuhuan Wang; Kai Su; Nadezhda S Sabeva; Ailing Ji; Deneys R van der Westhuyzen; Fabienne Foufelle; Xia Gao; Gregory A Graf
Journal:  Metabolism       Date:  2015-08-15       Impact factor: 8.694

9.  Combined effects of tauroursodeoxycholic Acid and glutamine on bacterial translocation in obstructive jaundiced rats:.

Authors:  Ahmet Rahmi Hatipoğlu; Serhat Oğuz; Saban Gürcan; Tülin Yalta; Doğan Albayrak; Cengiz Erenoğlu; Tamer Sağıroğlu; Yavuz Atakan Sezer
Journal:  Balkan Med J       Date:  2013-12-01       Impact factor: 2.021

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.